Company intelligence / Profile preview
Nanoligent
Barcelona, Catalonia, Spainnanoligent.com ↗
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
Nanoligent’s lead program targets the CXCR4 receptor to halt tumor growth and metastasis using a novel protein nanoparticle approach. The company has demonstrated promising preclinical results and aims to develop affordable, effective therapies with fewer side effects than traditional drugs. The technology holds potential for application beyond oncology. No published human clinical data as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Protein conjugates/nanoparticlesTargeted drug delivery systems
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
i&i Biotech Fund I (investment/strategic support)
Beyond the preview
Go deeper on Nanoligent.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanoligent.